The Present Years
This month we are featuring the current editors including Drs L. Gabriel Navar and Richard N. Ré, Associate Editors, and Dr Edward D. Frohlich, Editor-in-Chief. During our tenure (1994-present) we have witnessed an increasing interest in Hypertension so that in 1998, we received almost 1100 manuscripts, and the impact score is 4.94. Because of the very recent past and present tenure, it is difficult to identify those 25 papers with the greatest impact and frequency of reference because there is a close scoring among the top 30. They are listed below in alphabetical order by the first author. The editors hope that the readers were satisfied with this series of these successful 20 years. Next month we shall begin another series which we hope will strike your fancy as we celebrate the first 20 years of Hypertension.
Albaladejo P, Bouaziz H, Duriez M, Gohlke P, Levi BI, Safar ME, Benetos A. Angiotensin converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension. 1994;23:74–82.
Alderman MH, Madhavan S, Cohen H, Sealey JE, Laragh JH. Low urinary sodium is associated with greater risk of myocardial infarction among treated hypertensive men. Hypertension. 1995;25:1144–1152.
Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis: oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25:155–161.
Alonso-Galicia M, Drummond HA, Reddy KK, Falck JR, Roman RJ. Inhibition of 20-HETE production contributes to the vascular responses to nitric oxide. Hypertension. 1997;29:320–325.
Belloni AS, Rossi GP, Andreis PG, Neri G, Albertin G, Pessina AC, Nussdorfer GG. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27:1153–1159.
Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension. 1995;25:918–923.
Bernink PJ, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40–5967): a new generation of calcium antagonists? Mibefradil international study group. Hypertension. 1996;27:426–432.
Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension. 1994;23:195–199.
Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charrru A, Clauser E, Tiret L, Cambien F, Corvol P, Soubrier F. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension. 1994;24:63–69.
Booz GW, Baker KM. Role of Type 1 and Type 2 Angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635–640.
Brosnihan KB, Li P, Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 1996;27:523–528.
Bruckschlegel G, Holmer SR, Jandeleit K, Grimm D, Muders F, Kromer EP, Riegger GA, Schunkert H. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension. 1995;25:250–259.
Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population: results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25:305–313.
Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population: data from the Health Examination Surveys, 1960 to 1991. Hypertension. 1995;26:60–69.
Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439–449.
Campese VM. Salt sensitivity in hypertension: renal and cardiovascular implications. Hypertension. 1994;23:531–550.
Cockell AP, Poston L. Flow-mediated vasodilation is enhanced in normal pregnancy but reduced in preeclampsia. Hypertension. 1997;30:247–251.
d’Uscio LV, Moreau P, Shaw S, Takase H, Barton M, Luscher TF. Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension. 1997;29:435–441.
Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, Saxena PR, Schalekamp MA. Cardiac renin and angiotensins: uptake from plasma versus in situ synthesis. Hypertension. 1994;24:37–48.
de Gasparo M, Husain A, Alexander W, Catt KJ, Chiu AT, Drew M, Goodfriend T, Harding JW, Inagami T, Timmermans PB. Proposed update of angiotensin receptor nomenclature. Hypertension. 1995;25:924–927.
deBlois D, Tea BS, Than VD, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension. 1997;29:340–349.
Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression. Hypertension. 1994;23:587–592.
Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, Kleinert H. Nitric oxide synthase isozymes: characterization, purification, molecular cloning, and functions. Hypertension. 1994;23:1121–1131.
Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin-(1–7) inhibits vascular smooth muscle cell growth. Hypertension. 1996;28:104–108.
Fukuo K, Hata S, Suhara T, Nakahashi T, Shinto Y, Tsujimoto Y, Morimoto S, Ogihara T. Nitric oxide induces upregulation of fas and apoptosis in vascular smooth muscle. Hypertension. 1996;27:823–826.
Gasc JM, Shanmugam S, Sibony M, Corvol P. Tissue-specific expression of type 1 angiotensin II receptor subtypes: an in situ hybridization study. Hypertension. 1994;24:531–537.
Gerhard M, Roddy MA, Creager SJ, Creager MA. Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension. 1996;27:849–853.
Gohlke P, Linz W, Scholkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411–418.
Goldberg MR, Bradstreet TE, McWilliams EJ, Tanaka WK, Lipert S, Bjornsson TD, Waldman SA, Osborne B, Pivadori L, Lewis G, Blum R, Herman T, Abraham PA, Halstenson CN, Lo M-W, Lu H, Spector R. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37–46.
Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension. 1995;25:1345–1350.